Check Your Health: How RX Match can help find the right medication for you – KUTV 2News

Posted on April 25, 2020 by Danzig

KUTV

Rx Match is a test that analyze and interprets each patient;s unique genetic makeup to help doctors determine which medication and dosage might work best with the patient's genes.

"Rx Match is a molecular test that we use to look at a person's DNA to learn how the metabolize certain drugs," said Jason Gillman, Cancer Genomics Director, Intermountain Healthcare.

Variations in a person's DNA can impact how they metabolize and respond to different drugs. RX Match analyzes those variants using pharmacogenomics, a cutting edge field of precision medicine that studies how genes can relate to a patient's response of medication.

The test is a cheek swab, that is then sent to a lab. The results are returned to the doctor about 7 to 14 days later.

The RX Match report includes a response score on antidepressants, opioids, statins, immunosuppressants, antiabetics and many others.

By incorporating genomic information, doctors can pinpoint which medications are most likely to work for their patients. This may help reduce repeat visits for drug side effects.

:There are options there are different ways that we can be more precise in the ways that we prescribe. If a drug is not working or you feel like you might not be on the right drug speak with your physician to see if RX Match is a good match for you," said Gillman.

Joan Eggert has a history of hypertension.

"I've had high blood pressure since age 22. I've been on all kinds of medications up to three or more at once with not really great results," said Joan.

She was placed on a new blood pressure drug shortly before she went on vacation. While she was scuba diving in Fiji, she started to experience shortness of breath.

"Heard the gurgles in my lungs and knew I had Immersion Pulmonary Edema because I am a hyperbaric doctor," said Joan. "Finally we got to shore and after hours on oxygen, I was ok.

Joan was determined to figure out what went wrong. Eventually, she had an RX Match test done.

The test told her she didn't respond well to the medication she was on. Doctors switched her medication and now she is doing better.

"I finally got the answer to my question; the medication I was switched to, I don't metabolize properly," said Joan.

Talk with your doctor if you are interested in learning more about RX Match.

For more information, click here.

Follow Check Your Health on Facebook, Twitter, and YouTube.

View post:
Check Your Health: How RX Match can help find the right medication for you - KUTV 2News

Myriad Genetics Announces Publication of a Meta-Analysis Demonstrating the Clinical Utility of the GeneSight Psychotropic Test in People with Major…

Posted on April 20, 2020 by Danzig

SALT LAKE CITY, April 20, 2020 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN, Myriad or the Company), a global leader in molecular diagnostics and precision medicine, today announced the publication of a meta-analysis of four clinical trials demonstrating that the GeneSight Psychotropic test significantly improves clinical outcomes among patients with major depressive disorder (MDD). The article titled, The Clinical Utility of Combinatorial Pharmacogenetic Testing for Patients with Depression: A Meta-Analysis, appeared online in the journal Pharmacogenomics.

Many commercial insurers and health technology assessors in the United States and internationally consider meta-analyses the highest level of clinical evidence for the treatment of depression, said Bryan Dechairo, Ph.D., executive vice president of Clinical Development at Myriad. Our meta-analysis further demonstrates the consistent clinical utility of the GeneSight Psychotropic test across multiple cohorts of patients with depression. Importantly, the data showed that when clinicians used the GeneSight test to guide clinical care their patients achieved statistically significantly better remission, response and symptom improvement.

The analysis included data from four prospective, controlled trials that evaluated the clinical utility of the GeneSight test in 1,556 people with MDD and who had at least one prior antidepressant medication failure. All four studies evaluated remission, response, and symptom improvement outcomes using the 17-item Hamilton Depression Rating Scale (HAM-D17) among patients whose medication selection was informed by the GeneSight test results (guided care) compared to unguided care (treatment as usual). The results demonstrate that outcomes were significantly improved for patients whose care was guided by the GeneSight test compared to unguided care. Overall remission improved 49 percent (p=.001), response improved by 40 percent and (p<0.01) and symptoms improved 43 percent (p=0.019) relative to treatment as usual.

About GeneSight PsychotropicGeneSight Psychotropic is a pharmacogenomic test that analyzes clinically important variations in DNA. The results of the test can inform doctors about genes that may impact how their patients metabolize or respond to depression medications.

About Myriad GeneticsMyriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on three strategic imperatives: transitioning and expanding its hereditary cancer testing markets, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets. For more information on how Myriad is making a difference, please visit the Company's website: http://www.myriad.com.

Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice HRD, Vectra, Prequel, ForeSight, GeneSight and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G.

Safe Harbor StatementThis press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements related to the GeneSight Psychotropic test significantly improving clinical outcomes among patients with major depressive disorder; the ability of the GeneSight test to guide clinical care for patients; and the Company's strategic directives under the caption "About Myriad Genetics." These "forward-looking statements" are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by forward-looking statements. These risks and uncertainties include, but are not limited to: uncertainties associated with COVID-19, including its possible effects on our operations and the demand for our products and services; our ability to efficiently and flexibly manage our business amid uncertainties related to COVID-19; the risk that sales and profit margins of our molecular diagnostic tests and pharmaceutical and clinical services may decline; risks related to our ability to transition from our existing product portfolio to our new tests, including unexpected costs and delays; risks related to decisions or changes in governmental or private insurers reimbursement levels for our tests or our ability to obtain reimbursement for our new tests at comparable levels to our existing tests; risks related to increased competition and the development of new competing tests and services; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and pharmaceutical and clinical services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and pharmaceutical and clinical services, including our ability to successfully generate revenue outside the United States; the risk that licenses to the technology underlying our molecular diagnostic tests and pharmaceutical and clinical services and any future tests and services are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating our laboratory testing facilities and our healthcare clinic; risks related to public concern over genetic testing in general or our tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license or acquire; risks related to our projections about our business, results of operations and financial condition; risks related to the potential market opportunity for our products and services; the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests; the risk of patent-infringement claims or challenges to the validity of our patents or other intellectual property; risks related to changes in intellectual property laws covering our molecular diagnostic tests and pharmaceutical and clinical services and patents or enforcement in the United States and foreign countries, such as the Supreme Court decisions in Mayo Collab. Servs. v. Prometheus Labs., Inc., 566 U.S. 66 (2012), Assn for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576 (2013), and Alice Corp. v. CLS Bank Intl, 573 U.S. 208 (2014); risks of new, changing and competitive technologies and regulations in the United States and internationally; the risk that we may be unable to comply with financial operating covenants under our credit or lending agreements; the risk that we will be unable to pay, when due, amounts due under our credit or lending agreements; and other factors discussed under the heading "Risk Factors" contained in Item 1A of our most recent Annual Report on Form 10-K for the fiscal year ended June 30, 2019, which has been filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. All information in this press release is as of the date of the release, and Myriad undertakes no duty to update this information unless required by law.

Go here to read the rest:
Myriad Genetics Announces Publication of a Meta-Analysis Demonstrating the Clinical Utility of the GeneSight Psychotropic Test in People with Major...

Global Respiratory Infection Diagnostic Markets by Technology, PLEX, Place and Region – COVID-19 Impact & Forecasting/Analysis with Executive…

Posted on April 25, 2020 by Danzig

The "Respiratory Infection Diagnostic Markets by Technology, PLEX, Place and by Region with COVID-19 Impact & Forecasting/Analysis, and Executive and Consultant Guides 2020-2024" report has been added to ResearchAndMarkets.com's offering.

COVID-19 has broken open the market for point of care testing of respiratory infections. Now the competition for market share begins in earnest. Large new markets are opening up. In health facilities, clinics, physicians' offices and elsewhere. And let's not forget the screening market, not just for COVID, but for the rest of the 20 something respiratory pathogens as well. Multiplex vs single plex?

Explore the rapidly changing market as competitors jockey for position in new markets that are not yet well understood.

New technology is forever changing the diagnosis of respiratory infections. Shrinking time to result is opening up markets multiple times the size of current microbiology based practice. Diagnosis has already moved into the Emergency Room. It is now moving to the Physician's Office Lab. Could the Home be next?

The Multiplex factor is creating market confusion while lowering costs and improving care but important factors are holding back progress. The widespread nature of respiratory infections, (young people can get 8 colds a year) means that potential market sizes are enormous. Respiratory, already the largest infectious disease category could multiply in size. This is a growth opportunity for all diagnostic companies. Understand the opportunity and the risk with this in-depth report.

Key Topics Covered

i. Respiratory Infections Diagnostic Market - Strategic Situation Analysis and Impact of COVID-19

ii. Guide for Executives, Marketing, Sales and Business Development Staff

iii. Guide for Management Consultants and Investment Advisors

1. Introduction and Market Definition

1.1 What are Respiratory Infections?

1.2 The Role of Diagnosis & Treatment

1.3 Market Definition

1.3.1 Revenue Market Size

1.4 Methodology

1.4.1 Authors

1.4.2 Sources

1.5 A Spending Perspective on Clinical Laboratory Testing

1.5.1 An Historical Look at Clinical Testing

2. Market Overview

2.1 Players in a Dynamic Market

2.1.1 Academic Research Lab

2.1.2 Diagnostic Test Developer

2.1.3 Instrumentation Supplier

2.1.4 Distributor and Reagent Supplier

2.1.5 Independent Testing Lab

2.1.6 Public National/regional lab

2.1.7 Hospital lab

2.1.8 Physician Office Labs

2.1.9 Audit Body

2.1.10 Certification Body

2.2 Respiratory Infections

2.2.1 Upper vs. Lower - Marketing Implications

2.2.2 Understanding the Role of Pneumonia

2.2.3 Bacterial Infections

2.2.3.1 Streptococcal Infections

2.2.3.2 Acute Otitis Media

2.2.3.3 Bacterial Rhinosinusitis

2.2.3.4 Diphtheria

2.2.3.5 Pneumococcal Pneumonia

2.2.3.6 Haemophilus Pneumonia

2.2.3.7 Mycoplasma Pneumonia (Walking Pneumonia)

2.2.3.8 Chlamydial Pneumonias and Psittacosis

2.2.3.9 Health Care-Associated Pneumonia

2.2.3.10 Pseudomonas Pneumonia

2.2.3.11 Pertussis (Whooping Cough)

2.2.3.12 Legionnaires Disease

2.2.4 Tuberculosis - A Special Case

2.2.5 Viral Infections

2.2.5.1 The Common Cold

2.2.5.2 Influenza

2.2.5.3 Viral Pneumonia

2.2.5.4 SARS and MERS

2.2.5.5 Measles (Rubeola)

2.2.5.6 Rubella (German Measles)

2.2.5.7 Chickenpox and Shingles

2.2.6 Fungal and Other Pathogens

2.2.6.1 Histoplasmosis

2.2.6.2 Coccidioidomycosis.

2.2.6.3 Blastomycosis

2.2.6.4 Mucormycosis

2.2.6.5 Aspergillosis

2.2.6.6 Pneumocystis Pneumonia

2.2.6.7 Cryptococcosis

2.3 Diagnostics - A Changing Role

2.3.1 Historical Practice

2.3.2 Current Diagnostics

2.3.3 The Multiplex Vector

2.3.4 Future Diagnostics - The Question of When and Where

2.3.5 Respiratory Infection Diagnostics - The Destination

2.3.6 Diagnostics as Defensive Weapons

3. Market Trends

3.1 Factors Driving Growth

3.1.1. Syndromic Multiplexing

3.1.2 T.A.T

3.1.3 Antimicrobial Resistance Movement

3.1.4 Pandemic Mitigation

3.1.5 An Aging at Risk Population

3.2 Factors Limiting Growth

3.2.1 The Cost Curve

3.2.2 Regulation and coverage

3.2.3 Laissez Faire

3.3 Instrumentation and Automation

3.3.1 The Shrinking Multiplexing Machine

3.3.2 Bioinformatics Networking and Anonymous Reporting

3.4 Diagnostic Technology Development

3.4.1 The Key Role of Time to Result

3.4.2 Single Cell Genomics Changes the Picture

3.4.3 Pharmacogenomics Blurs Diagnosis and Treatment

3.4.4 Pathogen Identification - A Projected Timetable of the Future

Story continues

4. Respiratory Infection Diagnostics Recent Developments

4.1 Recent Developments - Importance and How to Use This Section

4.1.1 Importance of These Developments

4.1.2 How to Use This Section

5. Profiles of Key Players

6. The Global Market for Respiratory Infection Diagnostics

6.1 Global Market Overview by Country

6.1.1 Table - Global Market by Country

6.1.2 Chart - Global Market by Country

See more here:
Global Respiratory Infection Diagnostic Markets by Technology, PLEX, Place and Region - COVID-19 Impact & Forecasting/Analysis with Executive...

NCLA Warns FDA’s Over-regulation Will Adversely Affect Public Health During Crisis – GlobeNewswire

Posted on April 20, 2020 by Danzig

Washington, D.C., April 14, 2020 (GLOBE NEWSWIRE) -- If weve learned anything from the COVID-19 pandemic, it is that federal agencies that overstep their authority hinder the health and safety of Americans. Other recent regulatory actions by the Food and Drug Administration (FDA) threaten to undermine the ability of clinical laboratories to provide healthcare professionals and patients with information critical to optimizing drug usage and avoiding adverse events. The New Civil Liberties Alliance is especially concerned that the FDAs decision to prevent the dissemination of information related to the impact of genetic variants on drug response (Pharmacogenomics or PGx) will adversely affect public health.

Today NCLA, a nonpartisan, nonprofit civil rights group, filed commentsin support of the Citizen Petition filed on January 9, 2020, by Hyman, Phelps & McNamara, P.C. on behalf of the Coalition to Preserve Access to Pharmacogenomics (Pgx) Information. NCLAs comments focus on two concerns: (1) FDAs efforts to suppress truthful speech violate the First Amendment rights of clinical laboratories as well as of those doctors and patients who wish to receive PGx information from those labs; and (2) FDAs defense of its speech suppression cannot be reconciled with the U.S. Constitutions separation of powers. FDA claims unlimited administrative discretion to prohibit the operation of all clinical laboratories, but it does not have the power to prosecute only those laboratories that disseminate truthful information of which FDA disapproves.

FDAs position also raises significant due-process concerns because it deprives the regulated community of fair notice of how to conform its conduct to FDAs expectations and permits enforcement officials to make up the rules on the fly. Laboratories have long been at the forefront of efforts to quickly develop tests for detecting the presence of new pathogens; they need considerable flexibility to meet the publics time-sensitive need for such tests. FDA should rescind its speech-suppression policy for laboratories that engage in PGx testing. Any new FDA policy on PGx tests should be developed through a notice-and-comment rulemaking proceeding that complies with the Administrative Procedure Act.

NCLA released the following statements:

FDA simply lacks constitutional authority to adopt legislation of its own accord and then proceed to apply that legislation to the regulated community. Only Congress may adopt federal laws restricting individual liberty. FDA should grant the Citizen Petition filed by the Coalition.

Rich Samp, Senior Litigation Counsel, NCLA

Although the FDA claims its speech-suppression policy protects patients, FDAs restrictions on laboratories marketing LDTs are far more likely to cause harm than to benefit public health. Laboratories are in a unique position to disseminate truthful information about gene-drug associations for new drugs. FDAs policy denies patients optimal treatment.

Jared McClain, Staff Counsel, NCLA

ABOUT NCLA

NCLA is a nonpartisan, nonprofit civil rights group founded by prominent legal scholarPhilip Hamburgerto protect constitutional freedoms from violations by the Administrative State. NCLAs public-interest litigation and other pro bono advocacy strive to tame the unlawful power of state and federal agencies and to foster a new civil liberties movement that will help restore Americans fundamental rights.

For more information visit us online atNCLAlegal.org.

###

Read the rest here:
NCLA Warns FDA's Over-regulation Will Adversely Affect Public Health During Crisis - GlobeNewswire

How Coronavirus Pandemic Will Impact Growing Infrastructure Development Projects in Asia-Pacific to Fuel Growth of the Pharmacogenomic (PGx) Testing…

Posted on April 20, 2020 by Danzig

COVID-19 (Coronavirus) has resulted in many advantages and disadvantages for companies in the Pharmacogenomic (PGx) Testing market. Research report of this Pharmacogenomic (PGx) Testing market is highlights key strategies that can help reduce the impact of COVID-19 on diverse business practices.

Analysts of Fact.MR, in a recently published market study, shares important factors that are expected to shape the growth of the Pharmacogenomic (PGx) Testing market over the forecast period (20XX-20XX). The current trends, market drivers, strategic collaborations, and threats are thoroughly evaluated to provide a clear understanding of the current market landscape and the course the Pharmacogenomic (PGx) Testing market is likely to take over the upcoming decade.

Request Sample Report @ https://www.factmr.co/connectus/sample?flag=S&rep_id=3143

According to the report, the Pharmacogenomic (PGx) Testing market is poised to register a CAGR growth of ~XX% throughout the forecast period owing to several key factors including growing investments in the Pharmacogenomic (PGx) Testing space, innovations with a rise in the number of research and development projects. Fact.MR excels in latest research techniques while curating the market study and gather data from credible and trusted primary and secondary sources.

Important doubts pertaining to the Pharmacogenomic (PGx) Testing market addressed in the report:

The Pharmacogenomic (PGx) Testing market study provides a detailed understanding of the major players operating in the Pharmacogenomic (PGx) Testing market. Some of the leading players discussed

Request Methodology On This Report @ https://www.factmr.co/connectus/sample?flag=RM&rep_id=3143

Pharmacogenomic (PGx) Testing market segments covered in the report:

Competitive landscape

Comprehensive SWOT analysis of established market players is provided in the report along with critical data including the sales strategy, marketing strategy and pricing strategy adopted by each market player.

Ask analyst about this report at https://www.factmr.co/connectus/sample?flag=AE&rep_id=3143

Key takeaways that add value to our clients business needs?

Visit link:
How Coronavirus Pandemic Will Impact Growing Infrastructure Development Projects in Asia-Pacific to Fuel Growth of the Pharmacogenomic (PGx) Testing...

(2020-2025) Protein Detection and Quantitation Market Estimated To Experience A Hike in Growth | Global Industry Size, Growth, Segments, Revenue,…

Posted on April 14, 2020 by Danzig

Latest Trending Report onProtein Detection and Quantitation Market

The report titled Global Protein Detection and Quantitation Market is one of the most comprehensive and important additions to Alexareports archive of market research studies. It offers detailed research and analysis of key aspects of the global Protein Detection and Quantitation market. The market analysts authoring this report have provided in-depth information on leading growth drivers, restraints, challenges, trends, and opportunities to offer a complete analysis of the global Protein Detection and Quantitation market. Market participants can use the analysis on market dynamics to plan effective growth strategies and prepare for future challenges beforehand. Each trend of the global Protein Detection and Quantitation market is carefully analyzed and researched about by the market analysts.

Protein Detection and Quantitation Market competition by top manufacturers/ Key player Profiled: Thermo Fisher Scientific, Promega, Genecopoeia, Labome, Garland Science

Get PDF Sample Copy of the Report to understand the structure of the complete report:(Including Full TOC, List of Tables & Figures, Chart) : https://www.alexareports.com/report-sample/700682

Global Protein Detection and Quantitation Market is estimated to reach xxx million USD in 2020 and projected to grow at the CAGR of xx% during 2020- 2025. According to the latest report added to the online repository of Alexareports the Protein Detection and Quantitation market has witnessed an unprecedented growth till 2020. The extrapolated future growth is expected to continue at higher rates by 2025.

Based on region, the globalProtein Detection and Quantitation market has been segmented into Americas (North America ((the U.S. and Canada),) and Latin Americas), Europe (Western Europe (Germany, France, Italy, Spain, UK and Rest of Europe) and Eastern Europe), Asia Pacific (Japan, India, China, Australia & South Korea, and Rest of Asia Pacific), and Middle East & Africa (Saudi Arabia, UAE, Kuwait, Qatar, South Africa, and Rest of Middle East & Africa).

Protein Detection and Quantitation Market Segment by Type covers: Bradford, Coomassie, BCA

Protein Detection and Quantitation Market Segment by Industry: Pharmaceuticals and Pharmacogenomics, Diagnostic Research, Agricultural Biotechnology, Breeding and Animal Livestock

After reading the Protein Detection and Quantitation market report, readers get insight into:

*Major drivers and restraining factors, opportunities and challenges, and the competitive landscape*New, promising avenues in key regions*New revenue streams for all players in emerging markets*Focus and changing role of various regulatory agencies in bolstering new opportunities in various regions*Demand and uptake patterns in key industries of the Protein Detection and Quantitation market*New research and development projects in new technologies in key regional markets*Changing revenue share and size of key product segments during the forecast period*Technologies and business models with disruptive potential

Key questions answered in the report:

What will the market growth rate of Protein Detection and Quantitation market?What are the key factors driving the global Protein Detection and Quantitation market size?Who are the key manufacturers in Protein Detection and Quantitation market space?What are the market opportunities, market risk and market overview of the Protein Detection and Quantitationmarket?What are sales, revenue, and price analysis of top manufacturers of Protein Detection and Quantitation market?Who are the distributors, traders, and dealers of Protein Detection and Quantitation market?What are the Protein Detection and Quantitation market opportunities and threats faced by the vendors in the global Protein Detection and Quantitationindustries?What are sales, revenue, and price analysis by types and applications of Protein Detection and Quantitationmarket?What are sales, revenue, and price analysis by regions of Protein Detection and Quantitation industries?

Get a discount on this report now at https://www.alexareports.com/check-discount/700682

Table of ContentsSection 1 Protein Detection and Quantitation Product DefinitionSection 2 Global Protein Detection and Quantitation Market Manufacturer Share and Market Overview2.1 Global Manufacturer Protein Detection and Quantitation Shipments2.2 Global Manufacturer Protein Detection and Quantitation Business Revenue2.3 Global Protein Detection and Quantitation Market OverviewSection 3 Manufacturer Protein Detection and Quantitation Business Introduction3.1 Thermo Fisher Scientific Protein Detection and Quantitation Business Introduction3.1.1 Thermo Fisher Scientific Protein Detection and Quantitation Shipments, Price, Revenue and Gross profit 2014-20193.1.2 Thermo Fisher Scientific Protein Detection and Quantitation Business Distribution by Region3.1.3 Thermo Fisher Scientific Interview Record3.1.4 Thermo Fisher Scientific Protein Detection and Quantitation Business Profile3.1.5 Thermo Fisher Scientific Protein Detection and Quantitation Product Specification3.2 Promega Protein Detection and Quantitation Business Introduction3.2.1 Promega Protein Detection and Quantitation Shipments, Price, Revenue and Gross profit 2014-20193.2.2 Promega Protein Detection and Quantitation Business Distribution by Region3.2.3 Interview Record3.2.4 Promega Protein Detection and Quantitation Business Overview3.2.5 Promega Protein Detection and Quantitation Product Specification3.3 Genecopoeia Protein Detection and Quantitation Business Introduction3.3.1 Genecopoeia Protein Detection and Quantitation Shipments, Price, Revenue and Gross profit 2014-20193.3.2 Genecopoeia Protein Detection and Quantitation Business Distribution by Region3.3.3 Interview Record3.3.4 Genecopoeia Protein Detection and Quantitation Business Overview3.3.5 Genecopoeia Protein Detection and Quantitation Product Specification3.4 Labome Protein Detection and Quantitation Business Introduction3.5 Garland Science Protein Detection and Quantitation Business IntroductionSection 4 Global Protein Detection and Quantitation Market Segmentation (Region Level)4.1 North America Country4.1.1 United States Protein Detection and Quantitation Market Size and Price Analysis 2014-20194.1.2 Canada Protein Detection and Quantitation Market Size and Price Analysis 2014-20194.2 South America Country4.2.1 South America Protein Detection and Quantitation Market Size and Price Analysis 2014-20194.3 Asia Country4.3.1 China Protein Detection and Quantitation Market Size and Price Analysis 2014-20194.3.2 Japan Protein Detection and Quantitation Market Size and Price Analysis 2014-20194.3.3 India Protein Detection and Quantitation Market Size and Price Analysis 2014-20194.3.4 Korea Protein Detection and Quantitation Market Size and Price Analysis 2014-20194.4 Europe Country4.4.1 Germany Protein Detection and Quantitation Market Size and Price Analysis 2014-20194.4.2 UK Protein Detection and Quantitation Market Size and Price Analysis 2014-20194.4.3 France Protein Detection and Quantitation Market Size and Price Analysis 2014-20194.4.4 Italy Protein Detection and Quantitation Market Size and Price Analysis 2014-20194.4.5 Europe Protein Detection and Quantitation Market Size and Price Analysis 2014-20194.5 Other Country and Region4.5.1 Middle East Protein Detection and Quantitation Market Size and Price Analysis 2014-20194.5.2 Africa Protein Detection and Quantitation Market Size and Price Analysis 2014-20194.5.3 GCC Protein Detection and Quantitation Market Size and Price Analysis 2014-20194.6 Global Protein Detection and Quantitation Market Segmentation (Region Level) Analysis 2014-20194.7 Global Protein Detection and Quantitation Market Segmentation (Region Level) AnalysisSection 5 Global Protein Detection and Quantitation Market Segmentation (Product Type Level)5.1 Global Protein Detection and Quantitation Market Segmentation (Product Type Level) Market Size 2014-20195.2 Different Protein Detection and Quantitation Product Type Price 2014-20195.3 Global Protein Detection and Quantitation Market Segmentation (Product Type Level) AnalysisSection 6 Global Protein Detection and Quantitation Market Segmentation (Industry Level)6.1 Global Protein Detection and Quantitation Market Segmentation (Industry Level) Market Size 2014-20196.2 Different Industry Price 2014-20196.3 Global Protein Detection and Quantitation Market Segmentation (Industry Level) AnalysisSection 7 Global Protein Detection and Quantitation Market Segmentation (Channel Level)7.1 Global Protein Detection and Quantitation Market Segmentation (Channel Level) Sales Volume and Share 2014-20197.2 Global Protein Detection and Quantitation Market Segmentation (Channel Level) AnalysisSection 8 Protein Detection and Quantitation Market Forecast 2019-20248.1 Protein Detection and Quantitation Segmentation Market Forecast (Region Level)8.2 Protein Detection and Quantitation Segmentation Market Forecast (Product Type Level)8.3 Protein Detection and Quantitation Segmentation Market Forecast (Industry Level)8.4 Protein Detection and Quantitation Segmentation Market Forecast (Channel Level)Section 9 Protein Detection and Quantitation Segmentation Product Type9.1 Bradford Product Introduction9.2 Coomassie Product Introduction9.3 BCA Product IntroductionSection 10 Protein Detection and Quantitation Segmentation Industry10.1 Pharmaceuticals and Pharmacogenomics Clients10.2 Diagnostic Research Clients10.3 Agricultural Biotechnology Clients10.4 Breeding and Animal Livestock Clients

Do Inquiry About The Report Here: https://www.alexareports.com/send-an-enquiry/700682

About Us:Alexa Reports is a globally celebrated premium market research service provider, with a strong legacy of empowering business with years of experience. We help our clients by implementing decision support system through progressive statistical surveying, in-depth market analysis, and reliable forecast data.

More:
(2020-2025) Protein Detection and Quantitation Market Estimated To Experience A Hike in Growth | Global Industry Size, Growth, Segments, Revenue,...

Cyclica Forms Multi-Year and Multi-Project Drug Discovery Partnership with the Genome Institute of Singapore – Yahoo Finance

Posted on April 14, 2020 by Danzig

Cyclica announces a multi-year and multi-project collaboration with the Genome Institute of Singapore (GIS), a research institute under the Agency for Science, Technology and Research (A*STAR). Cyclica and GIS will carry out research efforts spanning from polypharmacology profiling to novel compound design for diverse drug discovery programs in oncology and related diseases. The collaboration will leverage GIS deep expertise in functional genomics, drug target discovery, and data analytics, and Cyclicas AI-augmented and proprietary, Ligand Design and Ligand Express platform.

The world-class team of scientists at GIS will conduct new compound design and off-target profiling to discover hits and subsequently develop the lead compounds. GIS will perform functional analyses and testing of compounds derived from Cyclicas drug discovery platform against gene targets of interest to GIS. This cross-border collaboration provides a unique opportunity to tailor drug identification and development efforts in a holistic way that will enable the advancement of precision medicine. By empowering researchers and healthcare institutes who are at the forefront of innovation, Cyclica and GIS will pave the way to decentralize the drug discovery process and develop the next generation of improved treatments for patients based on the individuals disease features.

Dr. Tam Wai Leong, Group Leader of Precision Oncology at GIS, said, "Applying AI-augmented approaches towards drug design is innovative and forward-looking. It has the potential to rapidly grow the arsenal of new drugs in our fight against diseases like cancer, especially in an era of genomic medicine where physicians and scientists can better define the underlying genetic and molecular drivers of cancers."

Professor Liu Jianjun, Deputy Executive Director at GIS, added, "Our ability to harness advanced genomic technologies has enhanced our discovery of genetic contributions to a spectrum of diseases, including cancer. Many of these important cancer drivers currently do not have drugs that target them. We believe that machine learning and deep learning models will shorten the time and cost for the development of new therapeutics, and are pleased to collaborate with Cyclica to further our efforts in developing therapeutics that can have a positive impact on patients."

"The calibre of genomic research at GIS is world-class. We are thrilled to have the opportunity to work with many leading scientists at GIS to innovate novel therapeutics, based on genomic discoveries, for a wide range of diseases. This opportunity to make a meaningful contribution and impact to patients are common values we share with our partners at GIS," said Dr. Verner De Biasi, VP, Global Head of Strategic Partnerships at Cyclica.

About Cyclica, Inc. (Cyclica)

Cyclica is a Toronto, Canada based biotechnology company that is decentralizing the discovery of new medicines with its integrated structure-based and AI-augmented drug discovery platform, Ligand Design and Ligand Express. Taken together Ligand Design and Ligand Express design advanced lead-like molecules that minimize unwanted off-target effects, while providing a holistic understanding of a molecule's activity through integrated systems biology and structural pharmacogenomics. Cyclicas differentiated platform opens new opportunities for drug discovery, including multi-targeted and multi-objective drug design, lead optimization, ADMET-property prediction, target deconvolution, and drug repurposing for a wide range of indications. With a world-class team with deep roots in industry and a first-in-class integrated drug discovery platform, Cyclica will spark a surge of innovation through a combination of venture creation and partnerships with early-stage and emerging biotech companies. By doing more with AI, Cyclica will revolutionize a system troubled with attrition and costly failures, accelerate the drug discovery process, and develop medicines with greater precision.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200414005071/en/

Contacts

Davesh Chauhandavesh.chauhan@cyclicarx.com

Original post:
Cyclica Forms Multi-Year and Multi-Project Drug Discovery Partnership with the Genome Institute of Singapore - Yahoo Finance

NCLA Warns FDAs Over-regulation Will Adversely Affect Public Health During Crisis – Yahoo Finance

Posted on April 14, 2020 by Danzig

NCLA Comments in Support of Citizen Petition Filed on Behalf of the Coalition to Preserve Access to Pharmacogenomics (PGx) Information, Docket No. FDA-2020-P-0152

NCLA released the following statements:

Rich Samp, Senior Litigation Counsel, NCLA

Jared McClain, Staff Counsel, NCLA

ABOUT NCLA

For more information visit us online atNCLAlegal.org.

###

Judy Pino, Communications DirectorNew Civil Liberties Alliance202-869-5218media@ncla.legal

Pharmacogenomics Market Is Set To Grow During 2020 To 2029 | Value Chain, Future Guidelines and Profit Margin – True Version

Posted on December 18, 2019 by Danzig

Global Pharmacogenomics Market Report concentrates on the strong analysis of the present state of Pharmacogenomics Market which will help the readers to develop innovative strategies that will act as a catalyst for the overall growth of their industry.

The Global Pharmacogenomics Market research report of competitive analysis, statistical analysis, development trend, end-user analysis, historical data and forecast from 2020-2029. The Pharmacogenomics Market providing a comprehensive analysis of the market share, growth, size, trend, demand, outlook, classification, revenue details, competitive scenario, industry analysis, markets forecast, manufacturers, type, application, and Pharmacogenomics industry overview. The global Pharmacogenomics market report provide complete information regarding different factors driving or constraining business sector development. It gives a forecast on the estimation of the way of Pharmacogenomics market development. Key players can consider statistics, tables & figures mentioned in this report for strategic planning which lead to the success of the organizations such as Dynamic DNA Laboratories, Assurex Health Inc, Thermo Fisher Scientific Inc, Abbott Laboratories, Empire Genomics LLC, Myriad Genetics Inc, Illumina Inc, OPKO Health Inc (GeneDx), Hoffmann-La Roche AG and OneOme LLC.

This Pharmacogenomics market report provides information regarding the revenue (USD Million) and volume (Kilo Tons) for the period 2019 to 2029. It further elaborates the market drivers which contribute to the growth. It then describes the restraints that are faced by the market. The market is classified into various segments with in-depth analysis of each segment for the study period. The report classifies the market into different segments based on Technology, Application, End User, And Region. These segments are studied in detail incorporating the market estimates and forecasts at the regional and country level. The segment analysis is useful in understanding the growth areas and probable opportunities of the market.

Click Here, And Download Free Sample Copy In Just One Single Step At:https://marketresearch.biz/report/pharmacogenomics-market/request-sample

****GET UPTO 25% OFF (Year Ending Offer)****

This report contains a complete product overview and its scope in the market to define the key terms and provide the clients a holistic idea of the market and its tendency. It comprehensively evaluates the global Pharmacogenomics market with different perspectives for the purpose of providing a detailed informative and accurate analysis of regional growth, competition, market segmentation, and other important aspects.

The Pharmacogenomics Market is segmented based on

Segmentation by technology:

Polymerase Chain ReactionMicroarraySequencingMass SpectrometryElectrophoresisOthersSegmentation by application:

OncologyInfectious diseasesCardiovascular diseasesNeurological diseasesPsychiatryPain managementOthersSegmentation by end user:

Hospitals and clinicsResearch institutionsAcademic institutes

Geographically, this report is segmented into several key Regions, with revenue (million USD), production, consumption, and market share and growth rate of Pharmacogenomics in these regions, from 20202 to 2029 (forecast), covering multiple geographies such as North America, South America, Europe, Asia-Pacific, and Middle East & Africa. Some of the major countries covered in this report are U.S., Canada, Germany, France, U.K., Netherlands, Switzerland, Turkey, Russia, China, India, South Korea, Japan, Australia, Singapore, Saudi Arabia, South Africa, and Brazil

Top key questions answered in this report:

1. What are the major factors influencing the growth of the market (opportunities, drivers, industry-specific challenges, growth potential, and risks)?

2. Which consumer segment accounted for the highest sales of Pharmacogenomics in 2020?

3. What are the business risks and factors concerning the market?

4. What are some of the most promising, high-growth opportunities for Pharmacogenomics market by Technology, Application, End User, And Region?

5. Which region offers the most lucrative opportunities for the market in 2020?

6. What Pharmacogenomics product types will be the most in-demand in the recent year?

7. What sales channel will account for the largest sales?

8. What are the major challenges facing the Pharmacogenomics market?

Customize Report AndInquiry For The Pharmacogenomics Market Report:https://marketresearch.biz/report/pharmacogenomics-market/#inquiry

If you wish to find more details of the report or want a customization, contact us. You can get a detailed of the entire research here. If you have any special requirements, please let us know and we will offer you the report as you want.

Who Are We?

Prudour Pvt. Ltd. (https://marketresearch.biz) is a specialized market research, analytics, and solutions company, offering strategic and tactical support to clients for making well-informed business decisions. We are a team of dedicated and impassioned individuals, who believe strongly in giving our very best to what we do and we never back down from any challenge.

Prudour Pvt. Ltd. offers services such as data mining, information management, and revenue enhancement solutions and suggestions. We cater to industries, individuals, and organizations across the globe, and deliver our offerings in the shortest possible turnaround time.

Our ever-growing team of experts and professionals from various streams and verticals bring along crucial tried-and-tested skills, approaches, and techniques to conduct research and analysis, and deliver accurate and reliable forecasts on all global markets. We constantly push the limits and boundaries as we surge ahead to being one among the most sought-after companies in the market research and solutions industry, and this we do with great pride. We never stop focusing on innovation and improvement, which results in significant value addition to our offerings, while at the same time we maintain stringent guidelines with regard to qualitative and quantitative analysis outputs and forecasts.

Mr. Benni Johnson

MarketResearch.Biz (Powered By Prudour Pvt. Ltd.)

420 Lexington Avenue, Suite 300

New York City, NY 10170,

United States

Tel: +1 347 826 1876

Website:https://marketresearch.biz

Email ID:inquiry@marketresearch.biz

Mr. Benni Johnson

MarketResearch.Biz (Powered By Prudour Pvt. Ltd.)

420 Lexington Avenue, Suite 300

New York City, NY 10170,

United States

Tel: +1 347 826 1876

Website:https://marketresearch.biz

Email ID:inquiry@marketresearch.biz

Find More Related Reports:

Coil Coatings Market

Extruded Snacks Market

Fluropolymer Market

Sludge Treatment Chemicals Market

Specialty Medical Chairs Market

Waste to Energy Market

Wind Turbine Market

Cold Plasma Market

Commercial Drone Market

Coriolis Meters Market

Food Packaging Technology & Equipment Market

Iron Oxide Market

Medical Foods Market

Phytonutrients Market

Sterilization Equipment Market

Read the original:
Pharmacogenomics Market Is Set To Grow During 2020 To 2029 | Value Chain, Future Guidelines and Profit Margin - True Version

Pharmacogenomics | Cleveland Clinic

Posted on April 18, 2019 by Danzig

Overview Overview

The Center for Personalized Genetic Healthcare (CPGH) offers comprehensive pharmacogenomics services to individuals who are not responding to medication regimens or who are experiencing adverse side effects.

CPGH offers pharmacogenomics counseling, which can be incorporated into your medical care.

Prior to requesting an appointment, you will need to obtain a referral from your physician. If you are a patient outside the Cleveland Clinic health system, please have your physician complete a referral form and fax to 216.445.6935. To learn more about how to prepare for your appointment, review the "Before Your Visit" tab.

The Center for Personalized Genetic Healthcare (CPGH) is committed to providing comprehensive clinical genetic services, education and support to patients and family members. Our team of genetic experts will work with other Cleveland Clinic primary care providers and specialists to personalize your care by incorporating your genetic information into your overall health care plan.

You should consider having a pharmacogenomic evaluation if you have a personal history or have concerns about the following:

Contact your primary care provider or the Center for Personalized Genetic Healthcare (CPGH) to discuss whether a pharmacogenomics consultation is appropriate for you.

Prior to requesting an appointment, you will need to obtain a physician referral. If you are a patient outside the Cleveland Clinic health system, please have your physician complete a referral form and fax to 216.445.6935.

If you are a patient outside the Cleveland Clinic health system, you should send an authorization for the release of medical records form to each external facility. You may arrange to have medical records faxed (30 pages or less) to our department at 216.445.6935 or sent postal mail.

Cleveland Clinic Center for Personalized Genetic Healthcare Attn: Pharmacogenomics Clinic 9500 Euclid Ave. NE50 Cleveland, OH 44195

To make the most out of your visit, you should gather medication and health history information prior to your appointment. It may be helpful for you to prepare a list of current and past medications. Specifically, you will want to consider the following:

We will provide personalized expert counseling and education to you and your family. During your visit, you will see a genetics expert (clinical geneticist) and a pharmacogenomics clinical specialist for a genetics evaluation. You may also be scheduled with other Cleveland Clinic providers during your visit depending on your medical needs and physician availability.

After your visit, it may take anywhere from a few days up to two weeks for your clinical appointment notes to reach the healthcare providers that you requested to receive a copy. We are also glad to communicate with your healthcare providers about your case as needed. You are always welcome to follow up with us with questions regarding your visit.

Genetics consult and testing are billed as two separate services.

If genetic testing is indicated, your genetics provider will discuss costs and insurance coverage during your appointment.

Some patients are concerned that their genetic information may be used against them. To learn about your patient rights and protections in place to prevent genetic discrimination, read this article on GINA.

To learn more about billing options and financial assistance, review our billing and insurance information.

To schedule an appointment, please call 216.636.1768 or 800.998.4785.

T Building - Center for Personalized Genetic Healthcare9204 Euclid Ave.Cleveland , OH 44195

Link:
Pharmacogenomics | Cleveland Clinic

Can connected healthcare lead to better patient outcomes? – EPM Magazine

Posted on December 18, 2019 by Danzig

Daniel Streetman,manager of referential content in the Metabolism, Interactions, & Genomics group with Clinical Effectiveness at Wolters Kluwer,discusses the potential for pharmacogenomics to transform prescribed drugs and reduce instances of adverse drug reactions.

Prescribing the correct drug to a patient at the correct dosage is one of the most common daily challenges faced by clinicians, especially when the drug triggers an unexpected side effect.

There are a variety of reasons why drug treatments might not work as anticipated, including the patients genetic profile. This is why more work is now taking place to understand the complex relationship between the genome and drug response, in the fast-growing field of pharmacogenomics.

Pharmacogenomics allows clinicians to use a patients genetic information to guide both drug and dose selection, meaning they become less reliant on a trial-and-error approach to prescribing. During the treatment assessment it quickly becomes possible to identify drugs likely to prove ineffective for a certain patient and whether there are unique dosing or side effect implications. With this added insight, pharmacogenomics could potentially be a game-changer for personalised medicine, having an impact across a wide range of disciplines.

A key challenge in increasing the use of genomics-based information is that many clinicians, operating under extreme pressure, dont understand it or havent had time to process it properly.

This is where clinical decision support tools like Lexicomp a point-of-care drug information resource from Wolters Kluwer has an important role to play in accelerating the use of pharmacogenomics, by making such data easier for clinicians to access.

Lexicomp has built genomics information into drug reference resources, with the aim of highlighting possibly important drug-gene pairings to clinicians in a clear, concise form, with actionable recommendations. The information should be readily available to any professional involved in drug administration, including hospital consultants, first responders, GPs and nurses as well as pharmacists.

Regulators are also encouraging the healthcare sector to embrace genomics. By providing guidance to drug companies on how to introduce biomarker information to their labelling, they have been helping legitimise the role of pharmacogenomics among the wider clinical community.

A major appeal of pharmacogenomics is that it has the potential to impact a wide range of clinical areas. Cardiology, psychology and oncology, for example, are all key areas of investigation. Some researchers also believe that an improved pharmacogenomics infrastructure could be the key to innovation in drug development for Alzheimers Disease, a condition that is projected to have a global cost to society of US$20.8 trillion between 2015-2050.

There is genuine optimism about the potential for pharmacogenomics to move into the mainstream over the next 5-10 years, especially as more patients genetic data becomes available. However, the growth of this new science could also bring challenges. One concern could be over-expectation about the possibilities of pharmacogenomics within the professional community and among patients. In a recent report into the ethics of pharmacogenetics, the Nuffield Council on Bioethics Report touched on the risk of over-promising when it said that genomics might not be about finding the right drug for the right person, but instead suggesting a potential drug preference for genetically defined groups.

Despite some of the concerns, the NHS is well-placed to drive the global pharmacogenomic agenda. The UK is already a pioneer in the field of genetic testing, with a history of sequencing genomes. The cutting-edge work into genomics by the NHS large teaching hospitals and the potential for knowledge and information-sharing between NHS Trusts could deliver these advances at scale and pace for patient benefit.

It will prove far harder for a genomic-based system to develop in countries where the healthcare system is fragmented and siloed and genetic data is less accessible.

The pace of change in genomics will be accelerated further by the new NHS Genomic Medicine Service, which should soon be operational, helping genomic screening and personalised treatments to become the norm. By 2025, it is predicted that half a million whole genomes should be sequenced through different NHS care pathways.

This scale of genomic data will be one of the key drivers to help turn pharmacogenomics from a promising new technology into a mainstream practice, leading to better and safe outcomes for patients.

Dr. Daniel S. Streetman, PharmD, MS, is the manager of referential content in the Metabolism, Interactions, & Genomics group with Clinical Effectiveness at Wolters Kluwer Health. He completed a research fellowship in clinical pharmacology, with an emphasis in pharmacogenomics, at Bassett Healthcare in Cooperstown, NY, and was a clinical faculty member at the University of Michigan for several years prior to joining Wolters Kluwer. Dr. Streetman continues to maintain an academic relationship with several schools, lecturing on pharmacogenomics and other topics.

Read the rest here:
Can connected healthcare lead to better patient outcomes? - EPM Magazine

Suicide research could be the mortality breakthrough of the 2020s – Health Data Management

Posted on January 22, 2020 by Danzig

Bloomberg--Whats the medical breakthrough that could save the most lives in the U.S. over the next ten years? In the 2020s, medical research will likely inch forward when it comes to major killers like heart disease and cancer. But the biggest potential to save lives could lie in learning to prevent suicide.

The rates of reported suicides have been creeping up over the last two decades. Even more disturbingly, CDC reports that the suicide death rate for teens increased 56 percent between 2007 and 2017. Rising suicide rates might be a result of many things rising levels of despair, the opioid epidemic, greater access to guns, even the proliferation of Internet groups that offer people advice on how to kill themselves. It could also be that more people are reporting suicides instead of concealing such deaths as accidents.

Its a surprisingly common form of deathmore prevalent than homicide or automobile accidents. Unlike cancer and heart disease, which are leading causes of death among the old, suicide robs people of decades of life. According to CDC statistics, it is the second most prevalent cause of death, after accidents, for people between 10 and 34 and fourth for people between 34 and 54.

Because it hasnt been all that thoroughly studied as a medical problem, theres room to cut down on that death toll even without any remarkable technological breakthrough. A streamlined three-digit suicide hotline number, approved last month by FCC, could become one of the great public health measures of the century. Further out on the frontier, researchers are having some success using artificial intelligence to identify suicidal peoplethose whose lives might be saved by talk therapy or drugs.

John Pestian, director of the computational medicine center at Cincinnati Childrens Hospital, explains that there are different kinds of suicides. Some are driven primarily by chronic mental illness, while others are more impulsive. Those with chronic mental illness may make repeated attempts. People have a powerful instinct to live, he says, and for their psychological pain to override this, it must be incredibly intense. Hes hoping to help such people through pharmacogenomicsfinding drugs that will ease their chronic emotional pain.

The more impulsive cases are simpler to preventthink of the teenager whose boyfriend or girlfriend just left, or a Wall Street trader who lost all his money, he says. If someone is going through an acute crisis and wants to jump out a window, the right words spoken at the right time might be the only treatment needed to save a life.

Renowned suicide researcher Edwin Schneidman writes in The Suicidal Mind that therapists can help people in this state by getting them to consider alternatives besides killing themselveshelping them see that that they have choices. He describes how he helped a suicidal college student who felt hopeless after she found out she was pregnant. He got her to consider which of her options was least terrible, and she recovered.

In the memorable 2003 New Yorker story Jumpers, Tad Friend describes conversations with several people who survived after jumping off the Golden Gate Bridge. They told him that they recognized their mistake before they hit the water: I instantly realized that everything in my life that Id thought was unfixable was totally fixableexcept for having just jumped, one said. Another left a note saying Im going to walk to the bridge. If one person smiles at me on the way, I will not jump.

To learn more about the reasons people decide to take their own lives, Pestian and other researchers are amassing troves of data. Right now, he says, he has the biggest collection of suicide notes in the country, as well as samples of speech and body language from suicidal patients. There are clues in these that therapists can look forand patterns that algorithms can use to identify those most at risk.

He says suicide hotlines are crucial, and he approves of the idea of amending the current one, created in 2005, from the usual ten digits to just three: 988. Even so, its not quite as simple as it sounds, he says: there will also have to be the right kinds of resources at the other end of the line.

According to one news story, an FCC committee estimated that those resources would cost $570 million in the first year and $175 million the next. This is pocket change compared with, say, routine mammography, which costs Americans billions and the value of which has been called into question.

As for AI, using algorithms to predict anyones behavior can sound scary, especially the use of systems that attempt to label Facebook users as suicidal from their posts or others that gather data from users smartphones. But Pestian believes that theres potential for AI to do much good in the area of suicide, as long as its only used to support human decision-making, and humans dont delegate the decision making to machines.

He has developed algorithms that work with what he calls sentiment dataacoustic, visual or language patterns that differ between the suicidal and non-suicidal. In a paper published in 2016 in the journal Suicide and Life-Threatening Behavior, he applied an algorithm to interviews with a sample of 379 people, some known to be suicidal, some diagnosed with mental illness but not suicidal, and a healthy control group. The algorithm used speech, facial expressions and body language to identify the suicidal group with 85 percent accuracy.

Thats not perfect, but its better than doctors can do. Pestian has recently gotten a contract with Oak Ridge National Laboratory to apply AI to the rampant problem of suicide among veterans. According to a report from the U.S. Department of Veterans Affairs, more than 6,000 veterans die by suicide every yeara rate 50 percent higher than that in the general adult population.

We may not know the reason for the rising suicide rate, but we do know it is killing too many people, and that those deaths ought to be preventable. While science has a pretty detailed understanding of cancer and heart problems, suicide was studied by relatively few researchers until recently.

Read the original post:
Suicide research could be the mortality breakthrough of the 2020s - Health Data Management

Pharmacogenomics Market: Predictable To Witness Sustainable Evolution over 2020-2030 – Cole of Duty

Posted on July 2, 2020 by Danzig

Prophecy Market Insights Pharmacogenomics market research report provides a comprehensive, 360-degree analysis of the targeted market which helps stakeholders to identify the opportunities as well as challenges during COVID-19 pandemic across the globe.

Pharmacogenomics Devices Market reports provide in-depth analysis of Top Players, Geography, End users, Applications, Competitor analysis, Revenue, Financial Analysis, Market Share, COVID-19 Analysis, Trends and Forecast 2020-2029. It incorporates market evolution study, involving the current scenario, growth rate, and capacity inflation prospects, based on Porters Five Forces and DROT analyses.

Get Sample Copy of This Report @ https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/244

An executive summary provides the markets definition, application, overview, classifications, product specifications, manufacturing processes; raw materials, and cost structures.

Market Dynamics offers drivers, restraints, challenges, trends, and opportunities of the Pharmacogenomics market

Detailed analysis of the COVID-19 impact will be given in the report, as our analyst and research associates are working hard to understand the impact of COVID-19 disaster on many corporations, sectors and help our clients in taking excellent business decisions. We acknowledge everyone who is doing their part in this financial and healthcare crisis.

Segment Level Analysis in terms of types, product, geography, demography, etc. along with market size forecast

Segmentation Overview:

The Pharmacogenomics research study comprises 100+ market data Tables, Graphs & Figures, Pie Chat to understand detailed analysis of the market. The predictions estimated in the market report have been resulted in using proven research techniques, methodologies, and assumptions. This Pharmacogenomics market report states the market overview, historical data along with size, growth, share, demand, and revenue of the global industry.

Request Discount @ https://www.prophecymarketinsights.com/market_insight/Insight/request-discount/244

Regional and Country- level Analysis different geographical areas are studied deeply and an economical scenario has been offered to support new entrants, leading market players, and investors to regulate emerging economies. The top producers and consumers focus on production, product capacity, value, consumption, growth opportunity, and market share in these key regions, covering

The comprehensive list of Key Market Players along with their market overview, product protocol, key highlights, key financial issues, SWOT analysis, and business strategies. The report dedicatedly offers helpful solutions for players to increase their clients on a global scale and expand their favour significantly over the forecast period. The report also serves strategic decision-making solutions for the clients.

Competitive landscape Analysis provides mergers and acquisitions, collaborations along with new product launches, heat map analysis, and market presence and specificity analysis.

PharmacogenomicsMarket Key Players:

Thermo Fisher Scientific Inc., Qiagen N.V., F.Hoffmann-La Roche AG, Abbot Laboratories, Diatech Pharmacogenetics, and Assurex Health Inc.

The study analyses the manufacturing and processing requirements, project funding, project cost, project economics, profit margins, predicted returns on investment, etc. With the tables and figures, the report provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market.

Stakeholders Benefit:

Get In-depth TOC @ https://www.prophecymarketinsights.com/market_insight/Global-Pharmacogenomics-Market-By-Technology-244

About us:

Prophecy Market Insights is specialized market research, analytics, marketing/business strategy, and solutions that offers strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high-value opportunities in the target business area. We also help our clients to address business challenges and provide the best possible solutions to overcome them and transform their business.

Mr Alex (Sales Manager)

Prophecy Market Insights

Phone: +1 860 531 2701

Email: [emailprotected]

VISIT MY BLOG:- https://prophecyconsumerelectronics.blogspot.com/

The rest is here:
Pharmacogenomics Market: Predictable To Witness Sustainable Evolution over 2020-2030 - Cole of Duty

Global Pharmacogenomics (PGx) by leading manufacturers with its application and types 2020 2025| Abbott Laboratories, Affymetrix, Inc. – News Log…

Posted on January 4, 2020 by Danzig

Los Angeles, United State,January 2020 :

The report attempts to offer high-quality and accurate analysis of the global Pharmacogenomics (PGx) market, keeping in view market forecasts, competitive intelligence, and technological risks and advancements, and other important subjects. Its carefully crafted market intelligence allows market participants to understand the most significant developments in the global Pharmacogenomics (PGx) market that are impacting their business. Readers can become aware of crucial opportunities available in the global Pharmacogenomics (PGx) market as well as key factors driving and arresting market growth. The research study also provides deep geographical analysis of the global Pharmacogenomics (PGx) market and sheds light on important applications and products that market players can focus on for achieving strong growth.

Major players profiled in the report

We follow industry-best practices and primary and secondary research methodologies to prepare our market research publications. Our analysts take references from company websites, government documents, press releases, and financial reports and conduct face-to-face or telephonic interviews with industry experts for collecting information and data. There is one complete section of the report dedicated for authors list, data sources, methodology/research approach, and publishers disclaimer. Then there is another section that includes research findings and conclusion.

Get PDF template of Pharmacogenomics (PGx) market report@ https://www.qyresearch.com/sample-form/form/994732/global-Pharmacogenomics-PGx-market

This report focuses on the global top players, coveredAbbott LaboratoriesAffymetrix, Inc.Assurex Health, IncAstrazenecaGeneDXIllumina, Inc.Laboratory Corporation of America HoldingsMyriad Genetics, Inc.Pathway GenomicsPfizer, IncQiagen, Inc.RochegTeva Pharmaceutical Industries Ltd.Thermo Fisher ScientificTransgenomic, Inc.

Market segment by Regions/Countries, this report coversNorth AmericaEuropeChinaRest of Asia PacificCentral & South AmericaMiddle East & Africa

Market segment by Type, the product can be split intoPolymerase Chain Reaction (PCR)MicroarraySequencingOther

Market segment by Application, the market can be split intoCardiovascular Diseases (CVD)Central Nervous System (CNS)Cancer/OncologyInfectious DiseasesOther

Market Forecasting

Besides short-term and long-term estimations related to the global Pharmacogenomics (PGx) market, we provide you with demand, consumption, growth, and various other forecasts. We take your specific requirements into consideration and provide you the most applicable forecasts for the market. You can simplify your critical decision-making process using our forecasts on the global market. Our unbiased insights into critical aspects of the market will assist you to strengthen your market position and ensure lasting success in the long run. They will also help you to address the challenges you face in the market when reaching your milestones.

Customized Research

Our analysts are not only experts in preparing accurate and detailed market research reports but also customizing them according to your business needs. We can customize this entire report on the global Pharmacogenomics (PGx) market and also specific sections such as financial analysis, competitive intelligence, insights and innovation, target market analysis, strategy and planning, and market analysis. Our report customization can cover merger and acquisition screening, IPO prospectus, economic impact analysis, industry benchmarking, competitive landscape, due diligence, and company analysis.

Apart from the sections mentioned above, our report on the global Pharmacogenomics (PGx) market can be customized keeping in view other aspects such as research and development landscape, patent analysis, product competition, mega trend analysis, marketing mix modeling, go-to-market strategy, technology, B2B survey, and strategic frameworks. Furthermore, you can ask for customization of market scenario analysis, strategic recommendations, market potential analysis, identification of opportunities, market forecasting, market entry, market sizing, market attractiveness, and market segmentation.

Table of Contents

Study Coverage: This is the first section of the report that includes highlights of market segmentation, years covered, study objectives, major manufactures of the global Pharmacogenomics (PGx) market, and product scope.

Executive Summary: Here, the report sheds light on production, revenue, consumption, and capacity of the market. It also brings to light macroscopic indicators, drivers, restraints, and trends of the market.

Manufacturer Profiles: This section gives broad analysis of key players of the global Pharmacogenomics (PGx) market on the basis of different factors such as recent developments, market share, and gross margin. It also provides SWOT analysis.

Production by Region: All of the regions analyzed in the report are studied here based on key factors such as production, revenue, market share, and import and export.

Consumption by Region: Each regional market studied here is analyzed on the basis of consumption and consumption share of the global market.

Market Size by Product: It includes price, revenue, and market breakdown analysis by type of product.

Market Size by Application: It includes consumption, breakdown data, and consumption share analysis by application.

The report answers several questions about the Pharmacogenomics (PGx) market includes:

What will be the market size of Pharmacogenomics (PGx) market in 2025?What will be the Pharmacogenomics (PGx) growth rate in 2025?Which key factors drive the market?Who are the key market players for Pharmacogenomics (PGx)?Which strategies are used by top players in the market?What are the key market trends in Pharmacogenomics (PGx)?Which trends and challenges will influence the growth of market?Which barriers do the Pharmacogenomics (PGx) markets face?What are the market opportunities for vendors and what are the threats faced by them?What are the most important outcomes of the five forces analysis of the Pharmacogenomics (PGx) market?

Get Customized Report in your Inbox within 24 hours@ https://www.qyresearch.com/customize-request/form/994732/global-Pharmacogenomics-PGx-market

Contact US:QY Research, INC.17890 Castleton, Suite 218,Los Angeles, CA 91748USA: +1 626 295 2442China: +86 1082 945 717Japan: +81 9048 009 273India: +91 9766 478 224Emails enquiry@qyresearch.com

The Innovations That Will Revolutionize Health Care in Colorado – 5280 | The Denver Magazine

Posted on December 28, 2019 by Danzig

Say goodbye to insulin injections and hello to snake toxins.

From penicillin to 3D-printed kidneys, the medical field has long served as a major catalyst of human ingenuity. In Colorado, that innovation doesnt appear to be slowing down. Centennial State institutions are helping pioneer treatments that could revolutionize health careboth today and in the years ahead.

A Gilded PillAbout 416,000 adults in Colorado suffer from diabetes. No wonder, then, that oral insulin (read: no more needles) is considered the holy grail of diabetes care. Denvers Creekside Endocrine Associates is part of the quest as one of only 37 places in the country testing an insulin pill developed by New Yorks Oramed Pharmaceutical. The key is ensuring the capsule reaches the liver before dissolving in stomach acid. If successful, the pill could also drastically lower the average cost of diabetes care, which is currently nearly $10,000 a year in the United States.

Conversation StarterThis past August, UCHealth introduced the world to Alexas nerdy cousin, Livi. An artificial-intelligence-based virtual assistant, Livi can be summoned on an Amazon Echo by saying Alexa, ask UCHealth. Users can then pepper her with commands like Email me information on Crohns disease or Find me a neurologist, and Livi will consult network sources to locate the information. UCHealth hopes to expand Livis capabilities over the next few years. This fall, for example, she was integrated into its electronic medical record system and mobile app so she can check your test results and appointment times.

Game TheoryIn 2017, Childrens Hospital Colorado unveiled one of the first full-time hospital gaming and technology departments in the world. Patients with movement-debilitating illnesses such as cerebral palsy get the much-needed, potentially dexterity-improving activity they require by donning virtual reality and augmented reality headsets and, for example, exploring alien planets. The diversions can also make it easier for kids to undergo difficult treatments: The anxiety a child feels before a lumbar puncturean injection of medicine into her spinal fluidmight be lessened if she can confront the procedure while wielding a lightsaber.

Snake Venom SalesmanA professor at the University of Northern Colorado might have finally found a way for serpents to pay penance for the whole exile-from-Eden thing: Stephen Mackessys Venom Analysis Lab, which launched in the mid-1990s, has shown that toxins from some venomous snakes are capable of preventing cancer cells from metastasizing. The next step (likely still years away) is finding an application method that would weaponize compounds in the venom against a humans cancer without harming the humans body.

Good GenesBoth Lutheran Medical Center and Kaiser Permanente are early practitioners of pharmacogenomicsbasically, how your DNA affects your bodys reactions to medicines. In Lutherans pilot program, primary care providers give some patients the option of a 20-second cheek swab. Pharmacists and doctors can use subsequent genetic-testing reports to provide recommendations, such as lowering a dosage because genetic traits reveal your body might absorb drugs faster or suggesting you avoid a particular medication.

This article appeared in the 2020 issue of 5280 Health.

The rest is here:
The Innovations That Will Revolutionize Health Care in Colorado - 5280 | The Denver Magazine

Pharmacogenomic (PGx) Testing Market Projected to Experience Major Revenue Boost during the Period between 2018-2028 – Health News Office

Posted on November 2, 2019 by Danzig

Report Description

A recent market intelligence report that is published by Data Insights Partner ontheglobal Waterproofing Chemicals marketmakes an offering of in-depth analysis of segments and sub-segments in the regional and internationalWaterproofing Chemicals market. The research also emphasizes on the impact of restraints, drivers, and macro indicators on the regional and globalWaterproofing Chemicals market overthe short as well as long period of time. A detailed presentation of forecast, trends, and dollar values of globalWaterproofing Chemicals market isoffered. In accordance with the report, theglobal Waterproofing Chemicals market isprojected to expand at a CAGR of10%over the period of forecast.

Market Insight, Drivers, Restraints& Opportunity of the Market:

Waterprofing chemicals are the chemical products which are used to protect the internal and external areas for water proofing for several types of materials (most particularly concrete and plastic materials). The key companies available in the market provide those water proofing chemicals as standard chemicals as well as customized on the basis of the requirements of the clients. The advantages for using the water proofing chemicals are excellent durability of the materials, prevention of honeycombing, improved surface finished, less damage by the chemicals present in the water etc. The global Waterproofing Chemicals market is primarily driven by the increasing cost effectiveness of water proofing chemicals, and high quality of constructions in coastal areas in developed nations. Conversely, the growth of the global Waterproofing Chemicals market would likely to restrain by the less adoption rate Waterproofing Chemicals in developing countries in the upcoming period. However, new product development, strategic alliances such as collaborations among key players, marketing activities etc. would provide the global Waterproofing Chemicals market an opportunity to propel during the forecast period. For instance, Berger Paints acquired a Kolkata based firm in October 2019- the Kolkata based firm which is a stalwart in making construction chemicals, also has another division related to waterproofing chemicals. On the other hand, Pidilite Industries India Private Limited, has fortified its marketing campaign to strengthen its Dr. Fixit, waterproofing chemicals division through the celebrity endorsement (or TVC campaign).

Request for Report Sample:https://datainsightspartner.com/request-for-sample?ref=130

Segment Covered:

This market intelligence report on the global Waterproofing Chemicals market encompasses market segments based on technology, application, chemicals, and country. On the basis of application, the global Waterproofing Chemicals market is segregated into floors and basements, waste and water management, tunnel liners, and roofing and walls. In terms of technology, the global Waterproofing Chemicals market is categorized coating and lams, integral systems, and preformed membranes. In terms of chemistry, the global market is classified into bitumen, PVC, TPO, EPDM, elastomars and others. By country/region, the global Waterproofing Chemicals market has been divided into North America (the U.S., Canada), Latin America (Brazil, Mexico, Argentina and other countries), Europe (Germany, France, the U.K., Spain, Italy, Russia, and other countries), Asia Pacific (India, Japan, China, Australia and New Zealand and other countries), Middle East and Africa (GCC, South Africa, Israel and Other countries).

Profiling of Market Players:

This business intelligence report offers profiling of reputed companies that are operating in the market. Companies such as SIKA AG, Fosroc International Limited, The DOW Chemical Company, BASF SE, Pidilite Industries Limited, Drizoro S.A.U., Mapei S.P.A, and others have been profiled into detail so as to offer a glimpse of the market leaders. Moreover, parameters such as Waterproofing Chemicals related investment & spending and developments by major players of the market are tracked in this global report.

Report Highlights:

In-depth analysis of the micro and macro indicators, market trends, and forecasts of demand is offered by this business intelligence report. Furthermore, the report offers a vivid picture of the factors that are steering and restraining the growth of this market across all geographical segments. In addition to that, IGR-Growth Matrix analysis is also provided in the report so as to share insight of the investment areas that new or existing market players can take into consideration. Various analytical tools such as DRO analysis, Porters five forces analysis has been used in this report to present a clear picture of the market. The study focuses on the present market trends and provides market forecast from the year 2017-2027. Emerging trends that would shape the market demand in the years to come have been highlighted in this report. A competitive analysis in each of the geographical segments gives an insight into market share of the global players.

Request for Report Analysis:https://datainsightspartner.com/report/waterproofing-chemicals-market/130

Salient Features:

This study offers comprehensive yet detailed analysis of theWaterproofing Chemicals market, size of the market (US$ Mn), and Compound Annual Growth Rate (CAGR (%)) for the period of forecast: 2019 2027, taking into account 2018 as the base year

It explains upcoming revenue opportunities across various market segments and attractive matrix of investment proposition for the said market

This market intelligence report also offers pivotal insights about various market opportunities, restraints, drivers, launch of new products, competitive market strategies of leading market players, emerging market trends, and regional outlook

Profiling of key market players in the worldWaterproofing Chemicals marketis done by taking into account various parameters such as company strategies, distribution strategies, product portfolio, financial performance, key developments, geographical presence, and company overview

Leading market players covered this report comprise names suchSIKA AG, Fosroc International Limited, The DOW Chemical Company, BASF SE, Pidilite Industries Limited, Drizoro S.A.U., Mapei S.P.A, andamong others

The data of this report would allow management authorities and marketers of companies alike to take informed decision when it comes to launch of products, government initiatives, marketing tactics and expansion, and technical up gradation

The world market forWaterproofing Chemicals catersto the needs of various stakeholders pertaining to this industry, namely suppliers, manufacturers, investors, and distributors forWaterproofing Chemicals market.The research also caters to the rising needs of consulting and research firms, financial analysts, and new market entrants

Research methodologies that have been adopted for the purpose of this study have been clearly elaborated so as to facilitate better understanding of the reports

Reports have been made based on the guidelines as mandated by General Data Protection Regulation

Ample number of examples and case studies have been taken into consideration before coming to a conclusion

Reasons to buy:

vIdentify opportunities and plan strategies by having a strong understanding of the investment opportunities in theWaterproofing Chemicals market

vIdentification of key factors driving investment opportunities in theWaterproofing Chemicals market

vFacilitate decision-making based on strong historic and forecast data

vPosition yourself to gain the maximum advantage of the industrys growth potential

vDevelop strategies based on the latest regulatory events. Identify key partners and business development avenues

vRespond to your competitors business structure, strategy and prospects. Identify key strengths and weaknesses of important market participants

Go here to see the original:
Pharmacogenomic (PGx) Testing Market Projected to Experience Major Revenue Boost during the Period between 2018-2028 - Health News Office

Manchester University to Add Master’s Degree in Nutrition – Inside INdiana Business

Posted on October 26, 2019 by Danzig

Grand Park Director Named to Board By Reed Parker Writer/Reporter2019-10-24T13:23:49Z

Grand Park Sports Campus Director William Knox has been named to the Advisory Board for Sportology 2020, a nationwide sports technology conference. Knox will discuss how technology can best support the sports industry and events community. The conference is set for March 2020 in Fort Worth, Texas. Knox holds a degree from Indiana University.

A new regional flight option is coming to Indianapolis. United Airlines will Sunday begin offering local customers flights on what it calls the worlds only two-cabin, 50-seat regional aircraft to Chicago OHare.

Zionsville-based 120WaterAudit has added two tech veterans to its executive team. The tech company, which provides a cloud-based water software platform, says the additions will support its continued momentum, following its recently-completed $7 million funding round.

While construction workers in Wisconsin were responsible for laying the keel of the brand new combat ship USS Indianapolis, the duty of commissioning the vessel is bestowed upon Indiana. The states first U.S. Navy vessel commissioning ceremony will take place Saturday at the Port of Indiana-Burns Harbor.

The vast expanse of wind turbines in northwest Indiana appears to be set for expansion. Northern Indiana Public Service Co., a subsidiary of Merrillville-based NiSource (NYSE: NI), and Texas-based EDP Renewables North America LLC have agreed to collaborate on a 302-megawatt wind farm in White County.

The global pharmacogenomics market generated $5,312.8 million in 2017 and is projected to reach $10,265.5 million by 2025, growing at a CAGR of 8.61%…

Posted on October 26, 2019 by Danzig

New York, Oct. 23, 2019 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Pharmacogenomics Market by Technology, Application, and End User: Opportunity Analysis and Industry Forecast, 2017 - 2025" - https://www.reportlinker.com/p05793256/?utm_source=GNW

The global pharmacogenomics market generated $5,312.8 million in 2017 and is projected to reach $10,265.5 million by 2025, growing at a CAGR of 8.61% from 2018 to 2025. Pharmacogenomics is the field of science that evaluates the genetic makeup of an individual that affects the response to drugs. Pharmacogenomics combines the knowledge of pharmacology and genomics. It deals with the interaction of genetic variation and its influence over the drug response in patients by correlating genetic expression and its variability leading to drugs efficacy or toxicity. There has been a surge in demand for the use of pharmacogenomics as a tool to customize and optimize drug therapy to suit the patients genomic profile ensuring maximum efficacy and minimal adverse effects. Pharmacogenomics is a branch which studies the correlation between the genomic profile of the patient and the effects of drug over it. Pharmacogenomics belongs to the field of personalized medicine that promises the development of pharmacogenomics-based diagnostics tests in which drugs and drug combinations are optimized suiting the individual genotype. Pharmacogenomics is a field of science dealing with the identification of single nucleotide polymorphism in the interspecies and the effects it has over the drug diagnosis test that is used to identify the best suited drug, which is expected to not have an adverse effect on the patient and help the drug act effectively on the target. There is an increase in the demand for pharmacogenomics-based drug discovery and diagnostics owing to growth in prevalence of cancer, drug recalls, surge in awareness of pharmacogenomics diagnosis for treatment of cancer, higher number of R&D studies, and rise in adoption of pharmacogenomics in the development of drugs for pain management with better efficacy. Government initiatives and huge investments by private companies in R&D drive the pharmacogenomics market. Furthermore, surge in the aging population and rise in the global incidences of cancer are anticipated to boost the market growth. The application of high throughput genomic technologies in biomedical research and therapeutic procedures accelerate the market progression. The global pharmacogenomics market is segmented based on technology, application, end user, and region. Based on technology, the market is segregated as polymerase chain reaction, microarray, sequencing techniques, mass spectrometry and electrophoresis. Based on application, the pharmacogenomics market is further categorized into cancer, cardiovascular diseases, infectious diseases, neurological diseases and pain management among others. Based on end user, it is segmented as hospitals & clinics, research institutions and academic institutes. Based on region, the market is studied across North America (U.S., Canada, and Mexico), Europe (Germany, France, the UK, and rest of Europe), Asia-Pacific (China, Japan, Australia, India, and rest of Asia-Pacific), and LAMEA (Brazil, and rest of LAMEA).

KEY MARKET BENEFITS The study provides an in-depth analysis of the global pharmacogenomics market share along with the current trends and future estimations to elucidate the imminent investment pockets. The report presents a quantitative analysis of the market to enable stakeholders to capitalize on the prevailing market opportunities. An extensive analysis of the market based on application assists in understanding the trends in the industry. The key market players along with their strategies are thoroughly analyzed to understand the competitive outlook of the industry.

KEY MARKET SEGMENTS

Market by Technology o Polymerase Chain Reaction o Microarray o Sequencing o Mass Spectrometry o Electrophoresis o Others

Market by Application o Oncology o Infectious diseases o Cardiovascular diseases o Neurological diseases o Psychiatry o Pain management o Others

By End User o Hospitals and clinics o Research institutions o Academic institutes

By Region North America o U.S. o Canada o Mexico Europe o Germany o France o UK o Rest of Europe Asia-Pacific o Japan o China o India o Australia o Rest of Asia-Pacific LAMEA o Brazil o Rest of LAMEA The list of key players operating in this market includes: Abbott Laboratories Admera Health Dynamic DNA Laboratories Empire Genomics, LLC F. Hoffmann-La Roche Ltd. Illumina, Inc OneOme, LLC Myriad Genetics Inc OPKO Health, Inc (GeneDx.) Thermo Fisher Scientific, Inc

The other players included in the value chain analysis (and not included in the report) include: Teva Pharmaceutical Industries Ltd. Assurex Health Inc. Admera Health Bayer AGRead the full report: https://www.reportlinker.com/p05793256/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

See original here:
The global pharmacogenomics market generated $5,312.8 million in 2017 and is projected to reach $10,265.5 million by 2025, growing at a CAGR of 8.61%...

Pharmacogenomics Program – mayo.edu

Posted on October 10, 2019 by Danzig

Drugs and Genes Conference

Getting you the right drug at the right dose at the right time is the goal of pharmacogenomics, which involves studying how your specific DNA sequence influences your response to medications.

The drugs available today to treat cancer, heart disease and other conditions are powerful agents that work as intended in most patients. Yet, in some people, a particular drug at the standard dose might not work well enough or may even trigger a serious adverse reaction. The reasons for this lie, at least in part, in your genes.

By using your unique genetic makeup as a factor when prescribing a drug for you, your doctor can maximize treatment effectiveness while avoiding potentially life-threatening side effects.

Pharmacogenomics can help us answer a broad range of questions, such as:

Results from a subset of the 77 "pharmacogenes" will be placed into the electronic health record (EHR) and an interpretive report will be placed into the patient's medical record.

Most electronic medical record systems are not equipped to alert the pharmacist or physician to these drug-gene interactions. The RIGHT10K study is utilizing the infrastructure built together with the RIGHT study at Mayo Clinic, which alerts to physicians in the drug prescription process so that patients get the right drug at the right time in the right amount.

The BEAUTY study performed whole-genome sequencing before and after neoadjuvant therapy (drug therapy before surgery) in women newly diagnosed with breast cancer.

Pharmacogenomics Program researchers are then comparing then compared the tumor genome before and after neoadjuvant therapy against the patient's germline genome the sequence of DNA in normal, noncancerous tissue in order to match the genomic response to therapy.

Read results of the BEAUTY study.

Based on the findings to-date from BEAUTY, clinicians are personalizing therapy to help ensure that women with breast cancer resistant to current therapy receive the right combination of drugs resulting in the highest chance of a cure. BEAUTY 2 participants will experience this approach and seamless health care in the treatment of breast cancer, during the crucial time between diagnosis and prior to surgery.

The PROMISE study will use participants' biopsies of metastatic breast cancer to obtain detailed information regarding the genetic makeup of the tumor as well as the host (germline) genome, with the goal of developing personalized treatment approaches to improve patient outcomes. Endocrine resistance is common in breast cancer patients, and while the drug palbociclib in combination with endocrine therapy has provided substantial improvements in progression free survival in women with metastatic breast cancer, that is not the case for all patients.

The PROMOTE study took an approach similar to the BEAUTY study, but for prostate cancer. The Pharmacogenomics Program hopes to elucidate the DNA sequences associated with response to therapy in order to identify new treatment options for patients with advanced prostate cancer that has resisted all conventional therapies.

This study also included groundbreaking work with mouse avatars, again to identify new and novel treatment options.

Patients with coronary artery disease often come into the emergency room requiring placement of one or more stents. In the TAILOR-PCI study, we are determining the specific DNA variant that might indicate whether the patient should receive the anticoagulant drug clopidogrel or an alternative drug, a question that has vexed cardiologists for years.

Safer and more effective treatment decisions will be systematically based upon genetic information.

Projects in Computational and Genomic Medicine, such as the joint NIH U54 and an NSFcenter grant project, blend the computational analysis, pharmacogenomics, and supercomputing expertise of the University of Illinois at Urbana-Champaign with the medical informatics and clinical practice expertise of Mayo Clinic. Researchers will develop new and innovative processes, such as artificial intelligence, that facilitate the translation of genomics and other high-dimensional data into clinical care.

The University of Illinois at Urbana-Champaign and Mayo Clinic as well as our affiliate, the University of Chicago, which are leading institutions in these areas and already have strong ties to each other, have established the Center for Computational Biotechnology and Genomic Medicine (CCBGM), a collaborative environment that will improve the applicability, timeliness, efficiency, and accuracy of the computational infrastructure that will address pressing genome-based challenges.

The Mayo Clinic and Illinois Strategic Alliance for Technology-Based Healthcare was organized in 2010 to advance research, technology, and clinical treatment options in health care. It's a collaboration of The Interdisciplinary Health Sciences Initiative at Illinois (IHSI).

The Alliance is a framework for collaboration in individualized medicine, and involves innovative educational programs, integrated research activities and projects, and entrepreneurial modes to deploy and commercialize outcomes.

BD2K funds research and training activities that support the use of Big Data to advance biomedical research and discovery. This includes efforts in enhancing training, resource indexing, methods and tools development, and other data science-related areas. As part of this NIH award, Mayo Clinic is developing tools for standardizing research metadata.

Richard Weinshilboum, M.D., director, Pharmacogenomics Program

Pharmacogenomic testing helps patient and her family members find answers to health-related questions.

The Pharmacogenomics Program investigates how variations in genes affect response to medications, thereby using a patient's genetic profile to predict a drug's efficacy, guide dosage and improve patient safety.

Sequencing uncovers genetic makeup of aggressive tumor.

The Center for Individualized Medicine is a strategic priority for the Campaign for Mayo Clinic.

Read more here:
Pharmacogenomics Program - mayo.edu

Precision medicine and pharmacogenomics – Mayo Clinic

Posted on March 29, 2019 by Danzig

Precision medicine and pharmacogenomics

Personalized medicine holds the promise that treatments will one day be tailored to your genetic makeup.

Modern medications save millions of lives a year. Yet any one medication might not work for you, even if it works for other people. Or it might cause severe side effects for you but not for someone else.

Your age, lifestyle and health all influence your response to medications. But so do your genes. Pharmacogenomics is the study of how a person's unique genetic makeup (genome) influences his or her response to medications.

Precision medicine aims to customize health care, with decisions and treatments tailored to each individual in every way possible. Pharmacogenomics is part of precision medicine.

Although genomic testing is still a relatively new development in drug treatment, this field is rapidly expanding. Currently, more than 200 drugs have label information regarding pharmacogenomic biomarkers some measurable or identifiable genetic information that can be used to individualize the use of a drug.

Each gene provides the blueprint for the production of a certain protein in the body. A particular protein may have an important role in drug treatment for one of several reasons, including the following:

When researchers compare the genomes of people taking the same drug, they may discover that a set of people who share a certain genetic variation also share a common treatment response, such as:

This kind of treatment information is currently used to improve the selection and dosage of drugs to treat a wide range of conditions, including cardiovascular disease, lung disease, HIV infection, cancer, arthritis, high cholesterol and depression.

In cancer treatments, there are two genomes that may influence prescribing decisions the genome of the person with cancer (the germline genome) and the genome of the cancerous (malignant) tumor (the somatic genome).

There are many causes of cancer, but most cancers are associated with damaged DNA that allows cells to grow unchecked. The "incorrect" genetic material of the unchecked growth the malignant tumor is really a separate genome that may provide clues for treatment.

One example is thiopurine methyltransferase (TPMT) testing for people who are candidates for thiopurine drug therapy. Thiopurine drugs are used to treat some autoimmune disorders, including Crohn's disease and rheumatoid arthritis, as well as some types of cancer, such as childhood leukemia.

The TPMT enzyme helps break down thiopurine drugs. People who are TPMT deficient don't break down and clear out these drugs quickly enough. As a result, the drug concentration in the body is too high and increases the risk of side effects, such as damage to the bone marrow (hematopoietic toxicity).

Genetic testing can identify people with TPMT deficiency so that their doctors can take steps to reduce the risk of serious side effects by prescribing lower than usual doses of thiopurine drugs or by using other drugs instead.

Although pharmacogenomics has great promise and has made important strides in recent years, it's still in its early stages. Clinical trials are needed not only to identify links between genes and treatment outcomes but also to confirm initial findings, clarify the meaning of these associations and translate them into prescribing guidelines.

Nonetheless, progress in this field points toward a time when pharmacogenomics will be part of routine medical care at least for some drugs.

See the original post here:
Precision medicine and pharmacogenomics - Mayo Clinic

Futurist Transhuman News Blog

Category Archives: Pharmacogenomics

Check Your Health: How RX Match can help find the right medication for you – KUTV 2News

Myriad Genetics Announces Publication of a Meta-Analysis Demonstrating the Clinical Utility of the GeneSight Psychotropic Test in People with Major…

Global Respiratory Infection Diagnostic Markets by Technology, PLEX, Place and Region – COVID-19 Impact & Forecasting/Analysis with Executive…

NCLA Warns FDA’s Over-regulation Will Adversely Affect Public Health During Crisis – GlobeNewswire

How Coronavirus Pandemic Will Impact Growing Infrastructure Development Projects in Asia-Pacific to Fuel Growth of the Pharmacogenomic (PGx) Testing…

(2020-2025) Protein Detection and Quantitation Market Estimated To Experience A Hike in Growth | Global Industry Size, Growth, Segments, Revenue,…

Cyclica Forms Multi-Year and Multi-Project Drug Discovery Partnership with the Genome Institute of Singapore – Yahoo Finance

NCLA Warns FDAs Over-regulation Will Adversely Affect Public Health During Crisis – Yahoo Finance

Pharmacogenomics Market Is Set To Grow During 2020 To 2029 | Value Chain, Future Guidelines and Profit Margin – True Version

Pharmacogenomics | Cleveland Clinic

Can connected healthcare lead to better patient outcomes? – EPM Magazine

Suicide research could be the mortality breakthrough of the 2020s – Health Data Management

Pharmacogenomics Market: Predictable To Witness Sustainable Evolution over 2020-2030 – Cole of Duty

Global Pharmacogenomics (PGx) by leading manufacturers with its application and types 2020 2025| Abbott Laboratories, Affymetrix, Inc. – News Log…

The Innovations That Will Revolutionize Health Care in Colorado – 5280 | The Denver Magazine

Pharmacogenomic (PGx) Testing Market Projected to Experience Major Revenue Boost during the Period between 2018-2028 – Health News Office

Manchester University to Add Master’s Degree in Nutrition – Inside INdiana Business

The global pharmacogenomics market generated $5,312.8 million in 2017 and is projected to reach $10,265.5 million by 2025, growing at a CAGR of 8.61%…

Pharmacogenomics Program – mayo.edu

Precision medicine and pharmacogenomics – Mayo Clinic